Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Italy fertility rate fell to new low of 1.14 in 2025 - 2April’s full pink moon will rise in the night sky this week
- 3Am I a Summer, or is this a scam? What I learned from color analysis.
- 4The most effective method to Keep up with Proficient Handshakes in a Computerized World
- 5Kobe Bryant called this WNBA star the 'Gold Mamba.' She turned his advice to her into a tattoo.
- Historic underwater structure discovered by divers off French coast
- IDF strikes Shiraz petrochemical site, releases footage of attacks on Iranian air defenses
- This Underrated Italian City Boasts Indulgent Food & Captivating Views For A Romantic Escape
- Ukraine's new defense minister just outlined how dire its troop shortage has become
- Display of Netanyahu's severed head 'incites public to murder PM', Likud says in official complaint
- Get To Be familiar with The Historical backdrop Of Western Medication
- Investigating Design and Individual Style: Track down Your Remarkable Look
- Italy now recognizes the crime of femicide and punishes it with life in prison
- ‘We are the alternative’: Anti-Hamas Gaza militia tells BBC group is receiving international support
